Johnson & Johnson says it's giving up its quest to expand the uses for its anemia drug Procrit, after a new clinical trial failed. Published in the New England Journal of Medicine today, the study didn't prove a decrease in red-blood-cell transfusions among critically ill patients taking Procrit.
The company had wanted to expand indications for Procrit to include all intensive-care patients with anemia, regardless of diagnosis. Currently, the drug is approved for anemic patients preparing for surgery or chemotherapy, and for those who also have HIV or kidney failure.
New study points to danger of anemia drug. Report
FDA considers anemia drug trials on safety concerns. Report
FDA panel votes for restrictions on anemia drugs. Report